US approves new treatment for pancreatic cancer

The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines’ targeted drug for adults with ​metastatic pancreatic cancer who have received prior treatment or ‌cannot receive combination chemotherapy.

Regulators gave expedited authorization to the novel pill, called daraxonrasib, which blocks a mutated protein driving tumor growth in over 90% of pancreatic cancer cases, a scientific approach that had previously eluded pharmaceutical researchers for decades.

The once-daily pill, called daraxonrasib and manufactured by Revolution Medicines, will be sold under the brand name Rasonque.

First-of-its-kind pill targets a mutation that fuels more than 90% of pancreatic cancers